Journal list menu
- Issue
Early View
Online Version of Record before inclusion in an issue
Export Citations
LETTER TO THE EDITOR
Trichoteiromania: A multicentre retrospective descriptive and analytical study of 129 cases
- Version of Record online: 09 January 2025
Concerns regarding the systematic review and editorial on oral dutasteride for frontal fibrosing alopecia
- Version of Record online: 08 January 2025
ORIGINAL ARTICLE
Trends in cutaneous melanoma mortality and incidence in European Union 15+ countries between 1990 and 2019
- Version of Record online: 08 January 2025
Almost all countries demonstrated increasing male ASDRs over the observation period. There was greater heterogeneity between countries regarding female ASDRs. The most recent Joinpoint analysis 2016–2019 shows significantly decreasing mortality in all countries except the United Kingdom. Incidence rates increased in all countries, with evidence of plateau from 2015 onwards.
Desmoplastic melanoma in Sweden in 2009–2022: A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends
- Version of Record online: 08 January 2025
The incidence of desmoplastic melanoma (DM) in Sweden remains stable, unlike rising cutaneous melanoma rates. Despite advanced tumour features, DM patients have better survival outcomes. However, recent survival improvements are lacking, potentially due to limited treatment options compared to other melanoma subtypes.
LETTER TO THE EDITOR
Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States
- Version of Record online: 07 January 2025
Response—Letter to the Editor: High-frequency ultrasound accuracy in preoperative cutaneous melanoma assessment
- Version of Record online: 07 January 2025
Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients
- Version of Record online: 06 January 2025
Causal association between body fat percentage and hidradenitis suppurativa: A two-sample Mendelian randomization study
- Version of Record online: 04 January 2025
Probing into functional decline among bullous pemphigoid patients: Letter in reply
- Version of Record online: 04 January 2025
Recibokibart, an anti-IL-36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
- Version of Record online: 04 January 2025
The impact of dupilumab on sleep disruptions in patients with prurigo nodularis: A systematic review and meta analysis
- Version of Record online: 31 December 2024
ORIGINAL ARTICLE
Impact of light dose and fluence rate on the efficacy and tolerability of topical 5-ALA photodynamic therapy for actinic keratoses: A randomized, controlled, observer-blinded intrapatient comparison study
- Version of Record online: 31 December 2024
In this randomized trial on the impact of modification of light dose and fluence rate in ALA-PDT for actinic keratoses, we found that halving the light dose and/or fluence rate did not negatively affect the therapeutic outcome. In addition, halving the fluence rate significantly decreased cPDT-induced pain during illumination.
LETTER TO THE EDITOR
Mycobacterium chelonae cutaneous infections unrelated to invasive procedures: A multicentre retrospective case series
- Version of Record online: 27 December 2024
Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors
- Version of Record online: 20 December 2024
Discovering basal cell carcinoma cellular origin via reflectance confocal microscopy
- Version of Record online: 19 December 2024
GUIDELINES
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
- Version of Record online: 19 December 2024
HISTORICAL PERSPECTIVE
Can Napoleon's skin disease and treatment be identified from paleoproteomic analyses of his last bathtub (1821)?
- Version of Record online: 19 December 2024
LETTER TO THE EDITOR
Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study
- Version of Record online: 19 December 2024
Fibrosis quantification in hidradenitis suppurativa tunnels: Histological correlation with shear wave elastography
- Version of Record online: 19 December 2024
Evaluating oral roflumilast in patients with hidradenitis suppurativa previously exposed to biologic treatment
- Version of Record online: 18 December 2024
Enhanced cardiovascular risks in patients with porphyria Cutanea Tarda: A retrospective cohort study
- Version of Record online: 18 December 2024
Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized clinical trial
- Version of Record online: 17 December 2024
Napkin psoriasis and the risk of later psoriasis development: A single-centre retrospective study
- Version of Record online: 17 December 2024
Lentigo maligna: A retrospective analysis of 50 cases treated with imiquimod monitored with non-invasive reflectance confocal microscopy
- Version of Record online: 17 December 2024
ORIGINAL ARTICLE
Line-field confocal optical coherence tomography coupled with artificial intelligence algorithms as tool to investigate wound healing: A prospective, randomized, single-blinded pilot study
- Version of Record online: 17 December 2024
Baseline dermoscopic patterns predict long-term changes in nevus diameter and in dermoscopic features
- Version of Record online: 16 December 2024
In the study, the authors have identified dermoscopic patterns that are associated with different stages in the life cycle of nevi. New nevi were associated with peripheral globules and smudgy patterns. Growing nevi were associated with peripheral globules and negative network patterns. Stable nevi were associated with reticular, structureless and central globules with peripheral network patterns.
LETTER TO THE EDITOR
Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real-word evidence analysis from the French national registry CARADERM
- Version of Record online: 16 December 2024
Spesolimab in refractory paediatric acrodermatitis continua of Hallopeau, a case series
- Version of Record online: 16 December 2024
POSITION STATEMENT
Oral health care pathways for patients with epidermolysis bullosa: A position statement from the European reference network for rare skin diseases
- Version of Record online: 13 December 2024
The European Reference Network for Rare Skin Diseases has developed consensus-based oral health care pathways for dental referral, treatment and follow-up for patients with EB according to their risk for oral and dental manifestations and complications. Referral for early preventive strategies is key to reducing the burden of disease.
LETTER TO THE EDITOR
Dapagliflozin-associated chronic balanitis due to Streptococcus agalactiae
- Version of Record online: 13 December 2024
ORIGINAL ARTICLE
Long-term follow-up of a randomized, double-blind, phase III, multi-centre study to evaluate the safety and efficacy of field-directed photodynamic therapy (PDT) of mild to moderate actinic keratosis using BF-200 ALA versus placebo and the BF-RhodoLED® lamp
- Version of Record online: 12 December 2024
Follow-up data 6 and 12 months after field-directed photodynamic therapy (PDT) for treatment of actinic keratosis (AK) in a phase III study. Sustained participant complete clearance. Participants who showed clinical complete clearance of AK lesions 12 weeks after PDT were assessed for recurrences. The sustained complete clearance was higher for BF-200 ALA than for placebo throughout the follow-up. Reduction in skin quality impairment. All parameters of skin quality improved during follow-up.
LETTER TO THE EDITOR
Infections and genotypes of Chlamydia trachomatis among men who have sex with men in China: A nationwide community-based study
- Version of Record online: 12 December 2024
CORRIGENDUM
Corrigendum to ‘Spatial transcriptomic analysis of tumour–immune cell interactions in melanoma arising from congenital melanocytic nevus’
- Version of Record online: 12 December 2024
LETTER TO THE EDITOR
Long-term real costs of a strategy using rituximab as first-line treatment for patients with moderate-to-severe pemphigus: Evaluation from the French healthcare system
- Version of Record online: 12 December 2024
ORIGINAL ARTICLE
Epidemiology and treatment of Adamantiades–Behçet's disease in Germany: A healthcare claims database study
- Version of Record online: 12 December 2024
LETTER TO THE EDITOR
Quantifying time to medical and/or surgical therapy after diagnosis of hidradenitis suppurativa and pilonidal sinus disease: A propensity-matched real-world cohort analysis
- Version of Record online: 11 December 2024
Dermatological societies and their climate change and sustainability commitment through 2024
- Version of Record online: 11 December 2024
Systemic anti-inflammatory therapy in congenital ichthyosis: Real-world experience in a series of 22 cases
- Version of Record online: 11 December 2024
The management of patients with delusional infestation across Europe
- Version of Record online: 11 December 2024
The association of Hidradenitis Suppurativa with comorbidities in underrepresented patient populations: An All of Us database analysis
- Version of Record online: 11 December 2024
Risk of blindness in a global cohort of patients with mucous membrane pemphigoid
- Version of Record online: 11 December 2024
ORIGINAL ARTICLE
Assessment of image quality on the diagnostic performance of clinicians and deep learning models: Cross-sectional comparative reader study
- Version of Record online: 10 December 2024
LETTER TO THE EDITOR
IL-24 for bullous pemphigoid severity: A case–control study
- Version of Record online: 09 December 2024
ORIGINAL ARTICLE
Effect of patient-contextual skin images in human- and artificial intelligence-based diagnosis of melanoma: Results from the 2020 SIIM-ISIC melanoma classification challenge
- Version of Record online: 08 December 2024
Effect of patient-contextual dermoscopy sets (right panel) was assessed. Participants classified (melanoma versus benign) the index lesion (blue border) before and after the remaining set was presented. Specificity decreased without significant change in sensitivity. 27.8% of human-readers outperformed the winning AI algorithm (AUROC = 0.930) from an online competition in enhanced-contextual assessment.
LETTER TO THE EDITOR
SYSTEMATIC REVIEW
Experience of patients and healthcare practitioners with interdisciplinary care in immune-mediated inflammatory diseases with skin manifestations: A systematic scoping review
- Version of Record online: 07 December 2024
This scoping review gathers evidence on patient- and HCP perceptions on interdisciplinary care (IC) for Immune-mediated inflammatory Diseases with Skin manifestations (skIMID) and state-of-the-art of measurement. IC experience is captured very heterogeneously and strongly depends on the context of the care provider. Experience seems to be better in local programmes than systems rolled out in larger geographical regions. Future need is to develop a standardized core IC outcome set, including medical-, process- and financial indicators, patient and HCP care experience measures. Such data will support benchmarking and identification of improvement areas in quality of care.
LETTER TO THE EDITOR
Upadacitinib for orofacial granulomatosis associated with Crohn's disease
- Version of Record online: 07 December 2024
Efficacy of olaparib combined with dabrafenib and trametinib for a patient with BRAF mutated and ATM deleted metastatic melanoma
- Version of Record online: 07 December 2024
ORIGINAL ARTICLE
Beyond the scoreboard: Coaches' UV-related skin cancer knowledge in outdoor sports
- Version of Record online: 05 December 2024
LETTER TO THE EDITOR
Robustness of automated acne lesion detection across various imaging conditions: A comparative analysis with dermatologists
- Version of Record online: 04 December 2024
Increased rates of complications in diabetic patients undergoing Mohs micrographic surgery: An international, propensity-matched, retrospective cohort study
- Version of Record online: 04 December 2024
Bimatoprost for the management of vitiligo: A systematic review and meta-analysis
- Version of Record online: 04 December 2024
Probing into functional decline among bullous pemphigoid patients
- Version of Record online: 03 December 2024
ORIGINAL ARTICLE
The integration of dermatology experts into primary care to assess and treat patients with skin lesions is cost-effective: A quasi-experimental study
- Version of Record online: 02 December 2024
The integration of dermatologist into primary care settings is cost-effective and streamlines the management of patients with skin conditions. The cost for each additional pre-malignancy or malignancy treated is €853 lower, and for any additional skin finding treated, €381 lower than that of the standard care pathway.
Line-field confocal optical coherence tomography of basal cell carcinoma: A retrospective study on diagnostic performance
- Version of Record online: 02 December 2024
LC-OCT markedly increases the diagnostic accuracy in the differentiation of BCC from imitators and in the discrimination across BCC subtypes. LC-OCT criteria such as lobule content, shape and location are crucial for BCC diagnosis and subtype classification. A straightforward, user-friendly diagnostic algorithm is proposed for BCC diagnosis and subtype discrimination.
LETTER TO THE EDITOR
Association of inflammatory skin biomarkers with clinical response in RGRN-305-treated patients with hidradenitis suppurativa
- Version of Record online: 02 December 2024
GUIDELINES
2024 European guidelines for the management of genital herpes
- Version of Record online: 02 December 2024
Genital herpes—guidelines for diagnostic and treatment (2024): strategies for diagnosis, management and follow-up of the most common sexually transmitted infection. The guidelines covers common clinical scenarios (including recurrent genital herpes), infection during pregnancy and coinfection with human immunodeficiency virus.
REVIEW ARTICLE
Topographical variations in the skin barrier and their role in disease pathogenesis
- Version of Record online: 28 November 2024
Unlike the gut, the skin appears uniform at first glance. However, histological and molecular biological research has revealed significant regional variations in the composition and function of its main barrier elements. In this review, we describe the topographical differences of four barrier elements in healthy skin: microbiome, chemical, physical and immunological barriers. We also discuss the role of these regional variations in the pathogenesis of certain inflammatory skin diseases.
Darier disease: Current insights and challenges in pathogenesis and management
- Version of Record online: 28 November 2024
Darier disease (DD) is characterized by the following: Disrupted Ca2+ gradients, impaired desmosomes, impaired keratinocyte differentiation, type 17 inflammation, DC and LC ↓, Th17 cells ↑. DD treatment: First line: keratinocyte focused and/or anti-inflammatory. Second line: experimental approaches like specific targeting of the inflammatory infiltrate.
LETTER TO THE EDITOR
Comparative analysis of temperature-controlled cryotherapy versus intralesional triamcinolone acetonide injection for alopecia areata: An intrasubject split-lesion pilot study
- Version of Record online: 28 November 2024
AI versus dermatologist performance in psoriasis body surface area assessment: A ground truth-validated, anatomical segment-based comparative study (AI PASS)
- Version of Record online: 28 November 2024
Objective actinic keratosis assessment by standardized clinical photography tool
- Version of Record online: 27 November 2024
Effects of comorbidities on delayed wound healing in patients with pyoderma gangrenosum
- Version of Record online: 26 November 2024
Prognosis of primary cutaneous angiosarcoma versus radiation-induced angiosarcoma: A cohort study
- Version of Record online: 26 November 2024
ORIGINAL ARTICLE
Trichophyton mentagrophytes ITS genotype VII infections among men who have sex with men in France: An ongoing phenomenon
- Version of Record online: 26 November 2024
We report 32 cases of infection by Trichophyton mentagrophytes ITS genotype VII, including a cluster of 17 cases, occurring in Paris, France between 2022 and 2023. Our findings confirm the circulation of the infection among men who have sex with men (MSM). The study highlights that the incubation period can be prolonged and is at risk of transmission. Topical antifungal treatments alone are often insufficient for achieving a cure, and oral treatments need to be prescribed for an extended duration. Additionally, patients remain contagious even after starting antifungal treatment.
LETTER TO THE EDITOR
Tinea barbae caused by T. mentagrophytes genotype VII, an emerging sexually transmitted infection among Men who have Sex with Men: A report from Milan, Italy
- Version of Record online: 26 November 2024
ORIGINAL ARTICLE
Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO study
- Version of Record online: 25 November 2024
Overall, 67 patients were included from 15 French centres (35 children and 32 adults). After the first sirolimus temporary withdrawal, mean time to recurrence of symptoms was 6.4 ± 9.6 months (survival curve). Sirolimus was overall well-tolerated (radar chart). Serious adverse events occurred in six patients (9.0%), especially respiratory infections. There were two cases of ovarian cysts. Conclusion. The real-life study SIROLO provides answers on persistence of efficacy over time, long-term side effects and time to recurrence in case of sirolimus withdrawal.
LETTER TO THE EDITOR
Lewis blood group antigens and ABH secretor status in patients with pemphigus
- Version of Record online: 22 November 2024
Number of melanoma deaths over time in relation to tumour thickness: Data from a Melanoma Unit Reference Center
- Version of Record online: 22 November 2024
Does early discontinuation of topical 4% 5-fluorouracil affect lesion clearance for actinic keratosis? Results from a dose-ranging study
- Version of Record online: 22 November 2024
Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year
- Version of Record online: 21 November 2024
Association of obesity with inflammatory skin disease: An inpatient population study
- Version of Record online: 21 November 2024
Genetic association of maternal smoking around birth with psoriasis: A two-sample Mendelian randomization analysis
- Version of Record online: 21 November 2024
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al.
- Version of Record online: 20 November 2024
Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption
- Version of Record online: 20 November 2024
ORIGINAL ARTICLE
Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy—A multicentre analysis
- Version of Record online: 20 November 2024
Background, key points, current state of management in dermato-oncology centres and algorithm for standardized monitoring and management of ICIPI; *routine radiographic imaging according to respective guidelines; **3 months after routine radiographic staging (6-monthly); ***if not recently performed as part of the routine staging. Abbreviations: ICI, Immune Checkpoint Inhibitor; ICIPI, Immune Checkpoint Inhibitor-Associated Pancreatic Injury; Q3M/Q6M, 3- and 6-monthly interval; Tx, treatment.
LETTER TO THE EDITOR
Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules
- Version of Record online: 20 November 2024
REVIEW ARTICLE
Review of doxycycline for prophylaxis of sexually transmitted infections
- Version of Record online: 18 November 2024
This study found that doxycycline prophylaxis offers signification reductions in common bacterial sexually transmitted infections (STIs), specifically in men who have sex with men. Both doxycycline pre- and post-exposure prophylaxis offer significant reduction in the transmission of STIs and have benign safety profiles. However, additional research is needed to determine the effects of doxycycline prophylaxis in other subpopulations as well as its effects on antimicrobial resistance.
LETTER TO THE EDITOR
“Terra firma-forme dermatosis” on the proximal nail fold
- Version of Record online: 16 November 2024
SYSTEMATIC REVIEW
Reflectance confocal microscopy for margin mapping of melanoma of the lentigo maligna type: A systematic review and meta-analysis
- Version of Record online: 15 November 2024
When compared with the gold standard histopathologic examination, the non-invasive RCM imaging technique has a negative predictive value (true negative margins confirmed by histopathology among all negative margins analysed by RCM) of 89.15%, highlighting its efficacy for margin mapping of melanoma of the lentigo maligna type.
In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis
- Version of Record online: 13 November 2024
Key confocal features in LM/LMM progression: Architecture: AIMP: Preserved; LM: Non-edged papillae; LMM: Epidermal/junctional disarray, collagen fibre destruction. Cellular distribution: AIMP: Junctional scattered atypical cells; LM: Widespread pagetoid and junctional atypical cells with junctional nests; LMM: Widespread pagetoid and junctional atypical cells with junctional and dermal nests. Cell Types: AIMP: Dendritic cells with mild atypia; LM/LMM: Dendritic cells with mild atypia, round nucleated cells with marked atypia.
LETTER TO THE EDITOR
Clinical characteristics of iatrogenic versus idiopathic linear IgA bullous dermatosis: A systematic review
- Version of Record online: 13 November 2024
ORIGINAL ARTICLE
Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2)
- Version of Record online: 13 November 2024
In FRONTIER-2 (NCT04212169), a Phase 2a, randomized, placebo-controlled study of 148 adults with moderate-to-severe atopic dermatitis, no statistically significant differences between tozorakimab and placebo were observed in the percentage change in EASI score from baseline to Week 16. The proportion of EASI-75 and IGA 0/1 responders at Week 16 was numerically higher in the tozorakimab 600 mg group than in the placebo group. Serum pharmacokinetics were dose-dependent, immunogenicity incidence was low and tozorakimab was well tolerated.
LETTER TO THE EDITOR
Psychological impact on flare patterns and severity of atopic dermatitis
- Version of Record online: 12 November 2024
Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN-FRT evaluation
- Version of Record online: 12 November 2024
Diagnostic wandering in hidradenitis suppurativa: A nationwide cohort study
- Version of Record online: 10 November 2024
Disagreement between physicians' and patients' assessment of disease activity in psoriasis: The SPEECH registry study
- Version of Record online: 09 November 2024
Reply to: Oral dutasteride is a first-line treatment for frontal fibrosing alopecia – There is insufficient evidence to recommend dutasteride as first-line treatment in frontal fibrosing alopecia
- Version of Record online: 08 November 2024
Keep the gauze in the box: A simple way to improve specimen preparation for the muffin micrographic surgery technique
- Version of Record online: 08 November 2024
Reply to ‘incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream’
- Version of Record online: 08 November 2024
Cardiovascular events in patients with psoriasis and psoriatic arthritis treated with JAK/TYK inhibitors: A systematic review and meta-analysis
- Version of Record online: 07 November 2024
Enhancing HFUS accuracy in melanoma assessment: The role of artificial intelligence and statistical precision
- Version of Record online: 05 November 2024
Intratumoural programmed cell death protein expression in 92 patients with atypical fibroxanthoma and pleomorphic dermal sarcoma
- Version of Record online: 05 November 2024
Nail clipping may not be sufficient to corroborate the diagnosis of psoriasis
- Version of Record online: 05 November 2024
Enhancement of sun-damaged skin qualities with tirbanibulin: A prospective Phase 4 study (SunDamage Study)
- Version of Record online: 05 November 2024
Consensus versus discordance in the classification of borderline melanocytic lesions between dermatopathologists and artificial intelligence: An Australian cohort study
- Version of Record online: 05 November 2024
Comment on ‘Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis’
- Version of Record online: 03 November 2024
POSITION STATEMENT
Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process
- Version of Record online: 26 October 2024
LETTER TO THE EDITOR
ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis
- Version of Record online: 24 October 2024
Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity’ by Dupuis et al.
- Version of Record online: 24 October 2024
ORIGINAL ARTICLE
Declining invasive and rising in situ melanoma incidence trends in Iceland: A nationwide cohort study
- Version of Record online: 24 October 2024
Utilizing the Icelandic Cancer Registry, this whole-population study found a surge in invasive and in situ melanoma incidence in the early 2000s. This surge was primarily observed in urban populations, with females consistently exhibiting higher incidence than males. Though incidence has decreased since the early 2000s, in situ melanomas are again on the rise in recent years in males and females, as well as invasive melanoma in rural females.
SYSTEMATIC REVIEW
Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Version of Record online: 24 October 2024
In this systematic review and network meta-analysis of Janus kinase (JAK) inhibitors for alopecia areata (AA), no evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on Severity of Alopecia Tool (SALT) ≤10 (odds ratio,OR: 0.96, 95% credible interval,CrI: 0.18–7.21) and SALT ≤20 (OR: 1.19, 95% CrI: 0.23–10.67) at Week 24 was found. Using individual patient data from the ALLEGRO trial (NCT03732807), evidence of effect modification by sex, SALT score at baseline, duration of current episode and disease duration was found, although the results were unchanged due to a small number of included trials. Further research on novel treatment for AA is warranted.
LETTER TO THE EDITOR
Refined prognostic stratification of cutaneous squamous cell carcinoma using top eight risk factors: A retrospective cohort study
- Version of Record online: 23 October 2024
Assessing dermatologists-venereologists' awareness, vigilance and attitude towards LGBT individuals: A cross-sectional study in Greece
- Version of Record online: 23 October 2024
Clearance of Darier disease lesions in a patient with concomitant atopic dermatitis treated with abrocitinib
- Version of Record online: 22 October 2024
The effect of cigarette smoking on Behcet's disease outcomes: A multicentre study
- Version of Record online: 21 October 2024
Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa
- Version of Record online: 19 October 2024
Association of MC1R variants with melanoma risk and interaction with sun exposure: An M-SKIP project
- Version of Record online: 19 October 2024
ORIGINAL ARTICLE
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials
- Version of Record online: 19 October 2024
Given that both dynamic IHS4 and dichotomous IHS4-55 use validated method of quantifying lesion types including draining tunnels, these results indicate that IHS4 and IHS4-55 can detect changes in response to treatment in clinical trial setting. DLQI, Dermatology Life Quality Index; HiSCR, hidradenitis suppurativa clinical response; HS, hidradenitis suppurativa; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg.
LETTER TO THE EDITOR
Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream
- Version of Record online: 17 October 2024
Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
- Version of Record online: 15 October 2024
GUIDELINES
Belgian recommendations for managing psoriasis in a changing treatment landscape
- Version of Record online: 12 October 2024
LETTER TO THE EDITOR
Epidemiological analysis of mycosis fungoides (MF) in children and young adult patient populations: A population-based analysis of the nationwide surveillance, epidemiology and end results (SEER) database
- Version of Record online: 12 October 2024
ORIGINAL ARTICLE
Impact of skin biopsy practices: A comprehensive nationwide study on skin cancer and melanoma biopsies
- Version of Record online: 12 October 2024
Skin biopsy decision-making is challenging. From a comprehensive national pathology registry including all biopsies, we investigated benign to malignant ratios (BMR) and number needed to biopsy (NNB) for lesions that might clinically mimic melanoma, for all biopsies and biopsies clinically suspected of cancer or melanoma. From 4.5 million included biopsies we found that (1) clinical suspicion of cancer impacts the BMR for malignancy and drastically affects the NNB for melanoma. (2) The amount of skin biopsies increased by 39% from 2007 to 2021. (3) The public funded healthcare system in Denmark spends €6.5M on benign skin lesions suspected of being melanoma—with the vast majority of these expenses from the hospital sector of the healthcare system. We therefore conclude that (1) layered triage helps separate low-risk from high-risk biopsies to achieve world-class NNB for melanoma and (2) it is crucial to include the clinical reason for biopsy in diagnostic accuracy studies focusing on NNB.
Psychometric properties of the revised internalized skin bias questionnaire
- Version of Record online: 09 October 2024
This two-part study included consensus-building surveys and a cross-sectional survey among participants with self-reported dermatological conditions to assess instrument psychometric properties of the revised Internalized Skin Bias Questionnaire (ISBQ-R). Overall, 33 experts participated including 22 (66.7%) dermatologists or dermatology researchers and 11 (33.3%) patients. The revised survey was completed by 214 participants with various dermatological conditions. Adding and modifying new items (9 in total) resulted in an instrument with stronger internal consistency (Cronbach's alpha = 0.92) and a stronger correlation with other existing stigma measures (ρ = 0.72) as well as health-related quality of life (ρ = −0.68), anxious (ρ = 0.51) and depressive (0.53) symptoms. Additionally, the study further expanded upon previous research by exploring a two-factor structure, suggesting that the ISBQ-R could be used as a single or dual factor instrument depending on investigator goals.
POSITION STATEMENT
Skin cancer in Europe today and challenges for tomorrow
- Version of Record online: 08 October 2024
Skin cancer represents a major challenge in the cancer field in Europe today and will continue to do so in the coming decades. This calls for a European skin cancer action plan intended to reduce avoidable UV exposure and to prepare the healthcare system to safeguard early diagnosis and treatment of skin cancer.
LETTER TO THE EDITOR
Reply to ‘Burnout and professional quality of life in dermatologists’
- Version of Record online: 04 October 2024
ORIGINAL ARTICLE
Hand eczema and changes in the skin microbiome after 2 weeks of topical corticosteroid treatment
- Version of Record online: 03 October 2024
Our results suggest that the microbiome, and not only Staphylococcus aureus, in moderate-to-severe hand eczema is significantly altered in lesional skin; however, shifting towards that of nonlesional skin following 2 weeks of treatment with a potent topical corticosteroid. We propose that the skin microbiome in hand eczema benefits from improved skin barrier function, that is, decreased disease severity, as seen in this study. Furthermore, this implies, that future research on microbial changes may generate therapeutic targets.
LETTER TO THE EDITOR
Phenolization as a treatment option for sinus tracts in hidradenitis suppurativa: A pilot study
- Version of Record online: 01 October 2024
ORIGINAL ARTICLE
Long-term remission of Hailey–Hailey disease by Er:YAG ablative laser therapy
- Version of Record online: 01 October 2024
Upper left panel: Hailey–Hailey lesion at baseline, directly after, 6 weeks and 3 years after a single Er:YAG laser ablation. Long-term remission was noted in 75/77 Hailey–Hailey plaques after a median follow-up of 38 months. Upper right panel: Median quality of life scores at baseline, 6 weeks and 3 years after laser ablation with a significant improvement at 6 weeks and 3 years after laser ablation. Bottom left panel: Electron microscopy of keratinocytes in the stratum spinosum at baseline and 6 weeks after laser ablation. Laser-treated skin showed an increased number of desmosomes, decreased intercellular distance and decreased perinuclear retraction of keratin filaments. Bottom right panel: Cross-section of the skin on the right side showing the depth of laser ablation. Laser ablation up to mid-dermis induced long-term remission of Hailey–Hailey disease.
LETTER TO THE EDITOR
Oesophageal lichen planus: Clinical, endoscopic and fibroscopic characteristics
- Version of Record online: 26 September 2024
Mycophenolate mofetil as a steroid-sparing agent in oral mucous membrane pemphigoid: A retrospective review
- Version of Record online: 26 September 2024
Combining an anti-IL-4Rα biologic with a JAK1 inhibitor leads to a higher treatment response in resistant atopic dermatitis versus monotherapy alone: A case series
- Version of Record online: 25 September 2024
ORIGINAL ARTICLE
Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome
- Version of Record online: 24 September 2024
This study found that all aspects of HRQL were compromised in patients with relapsed/refractory stage IB–IVB MF/SS. Different aspects of HRQL were worse in patients who were female, younger, Black/African American or who had worse mSWAT score, itch or performance status. Understanding of the individual's symptom burden, including patient-reported measures, should be used to inform treatment goals and therapeutic choice.
LETTER TO THE EDITOR
Comment on ‘Efficacy of interventions for cutaneous squamous cell carcinoma in situ (Bowen's disease): A systematic review and meta-analysis of proportions’
- Version of Record online: 23 September 2024
Sentinel lymph node biopsy may no longer be a critical component of melanoma management
- Version of Record online: 23 September 2024
Mental health in hidradenitis suppurativa: A complex matter
- Version of Record online: 21 September 2024
Tangential biopsy of the nail bed and matrix, with plate evaluation, for diagnosis of lichen planus
- Version of Record online: 20 September 2024
B-type natriuretic peptide levels are associated with chronic itch: A case–control study
- Version of Record online: 20 September 2024
Response to ‘Enhancing multimodal deep learning for improved precision and efficiency in medical diagnostics’
- Version of Record online: 20 September 2024
ORIGINAL ARTICLE
Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real-world data from a multicentre study
- Version of Record online: 19 September 2024
Methotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real-world effectiveness remain limited. This study aimed to assess real-world outcomes of oral MTX in the treatment of MF. Data from five referral centres for cutaneous lymphoma in Greece were retrospectively reviewed with the baseline- and treatment-related characteristics of patients extracted and analysed accordingly. In total, 211 patients were included in the study. MTX demonstrated greater effectiveness as a first-line treatment compared to subsequent use with no significant differences between monotherapy and combination therapy. No significant differences were observed between MTX monotherapy and MTX combined with other treatments. Patients with early-stage disease (IA-IIA) achieved favourable outcomes along with patients with erythrodermic disease (Stage III). Patients with Stage IV and IIB disease had the worst responses. The presence of the folliculotropic variant of MF did not affect responses to treatment while large cell transformation had a negative impact on responses. Overall, MTX demonstrated acceptable safety and a small amount of patients discontinued the medication due to adverse events. The findings of this large multicentric study support MTX as a viable treatment option for MF, particularly when used in the first line setting, offering a favourable benefit/risk profile. Response rates are stage-dependent, with erythrodermic patients achieving superior and durable responses.
LETTER TO THE EDITOR
Improvements in patient-reported outcomes with oral roflumilast for psoriasis: Results from a randomized controlled trial (PSORRO)
- Version of Record online: 19 September 2024
REVIEW ARTICLE
Bullous pemphigoid burden of disease, management and unmet therapeutic needs
- Version of Record online: 19 September 2024
A graphical abstract illustration including a summary of the manuscript, the epidemiology and clinical presentation of bullous pemphigoid (BP) and the effect on quality of life, diagnosis and management. ABSIS, autoimmune bullous skin disease intensity score; BPDAI, bullous pemphigoid disease area index; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQoL 5-dimensional questionnaire; GHQ-28, Generalized Health Questionnaire-28; SF-36, 36-Item Short Form.
LETTER TO THE EDITOR
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitis
- Version of Record online: 18 September 2024
Low-dose oral minoxidil for the treatment of monilethrix: A retrospective review
- Version of Record online: 18 September 2024
A cluster of early syphilis cases with ocular manifestations on the island of Crete
- Version of Record online: 18 September 2024
ORIGINAL ARTICLE
Educational, labour market and relationship outcomes in people with acne
- Version of Record online: 18 September 2024
In this study, Danish patients with acne had a lower risk of not completing upper secondary education (relative risk (RR): 0.79; 95% confidence interval [CI]: 0.76–0.83) and higher education (RR: 0.90; 95% CI: 0.88–0.91), slightly higher income (mean percentile difference: 2.6%, 95% CI: 2.2–2.9) and lower risk of long-term unemployment than those without acne (9.8% vs. 11.4%; RR: 0.90; 95% CI: 0.87–0.93). The prevalence of being single until age 30 was similar (19.7% vs. 20.1%; adjusted RR: 0.96; 95% CI: 0.94–0.98) but childlessness was slightly more prevalent (60.5% vs. 57.5%; adjusted RR: 1.03; 95% CI: 1.02–1.04). However, all associations were attenuated or lost in a secondary analysis restricted to exposure-discordant siblings to address confounding from family-related factors.
Identification of two molecularly and prognostically distinct subtypes in acral melanoma using network prediction method
- Version of Record online: 16 September 2024
A novel disease classification method is constructed using the combination of multi-omics data analysis and network-based disease gene prediction algorithm CIPHER-SC. It showed that the presence of two acral melanoma subtypes which greatly differed in clinical performance, cellular and molecular mechanisms and discovered a biomarker panel that accurately distinguished these two subtypes, which has been verified by clinical samples.
LETTER TO THE EDITOR
ChatGPT and acne: Accuracy and reliability of the information provided—The AI-check study
- Version of Record online: 16 September 2024
Evidence of early coronary atherosclerotic plaque in hidradenitis suppurativa compared to the background population is indicative of myocardial infarction risk
- Version of Record online: 16 September 2024
Anti-IL-23 therapy for the treatment of moderate-to-severe inverse psoriasis: A 52-week multicenter study
- Version of Record online: 13 September 2024
The development and validation of an investigator global assessment score for keratosis pilaris
- Version of Record online: 13 September 2024
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study
- Version of Record online: 13 September 2024
SYSTEMATIC REVIEW
Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments
- Version of Record online: 13 September 2024
Impact of Acne Therapies on the Skin Microbiome: This graphical abstract illustrates how various acne treatments affect the cutaneous microbiome, particularly focusing on Cutibacterium acnes and overall microbial diversity. Common treatments like doxycycline and benzoyl peroxide generally decrease C. acnes and reduce alpha diversity, while isotretinoin has variable effects. Newer therapies, including probiotics and plant extracts, are highlighted for their potential to restore microbial balance, suggesting a shift towards microbiome-focused treatment strategies.
LETTER TO THE EDITOR
Advanced age and dermoscopic streaks increase the likelihood of a diagnostic upgrade of ambiguous melanocytic tumours after clinicopathological correlation
- Version of Record online: 13 September 2024
Efficacy of dupilumab against pruritus in dystrophic epidermolysis bullosa: Real-life data from a retrospective bicentric study
- Version of Record online: 13 September 2024
SYSTEMATIC REVIEW
The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review
- Version of Record online: 13 September 2024
This study systematically analysed peer-reviewed publications describing use of the DLQI in validation of other PRO and QoL measures and identified widespread use of the DLQI as a benchmark in validation of other dermatology PRO/QoL measures. It confirms the central role DLQI plays in the development of novel instruments and validation across dermatology and beyond.
LETTER TO THE EDITOR
Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile
- Version of Record online: 12 September 2024
Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma-associated leptomeningeal disease
- Version of Record online: 12 September 2024
REVIEW ARTICLE
Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences
- Version of Record online: 11 September 2024
Hair Regrowth in Alopecia Areata. This scheme summarizes recent findings in hair follicle stem cell biology and their implication to regrow hair in alopecia areata. Hair follicle stem cells reside in hair bulge abundantly. Anagen drivers are enhanced and suppressed expression levels of activators and repressors at telogen, respectively. Noradrenaline secreted from niche activates hair follicle regeneration via ADRB2, FOXP1 and FGF18. Hair plucking at high density regenerate hair follicles via TNF-α. JAG1 + regulatory T lymphocytes regenerate hair follicles. Loss of COL17A1 results in hair follicle miniaturization. Burgundy and navy arrows indicate downregulation and upregulation, respectively. ADRB2, adrenergic receptor B2; BMP2, bone morphogenic protein 2; COL17A1, collagen XVII; DKK1, dickkopf 1; FGF18, fibroblast growth factor 18; FOXP1, forkhead box P1; JAG1, jagged 1; SFRP4, secreted frizzled-related protein 4; SHH, sonic hedgehog; TNFα, tumour necrosis factor-α. Re-pigmentation in Vitiligo. This scheme summarizes recent findings in melanocyte stem cell biology and their implication to re-pigment vitiligo skin. Melanocyte stem cells reside in lower portion of hair bulge and hair germ at telogen phase and contribute to perifollicular re-pigmentation. Amplifying melanocytes tend to lose proliferation and migration potential. BMI + CXCR2 + melanocyte stem cells exist in interfollicular epidermis and may contribute to marginal re-pigmentation. Hair follicle stem cells regulate melanocyte stem cells via cKIT, Wnt and other signals. PAX3 activates MITF, followed by DCT activation, whereas PAX3 directly downregulates DCT and maintains stemness. Noradrenaline induces melanocyte stem cell differentiation and migration via ADRB2. BMI1, B lymphoma Mo-MLV insertion region 1; cKIT, receptor tyrosine kinase for stem cell factor; CXCR2, chemokine C-X-C motif receptor 2; DCT, dopachrome tautomerase; MCAM, melanoma cell adhesion molecule; MITF, microphthalmia associated transcription factor; PAX3, paired box gene 3. Melanocyte Distribution Pattern Differences. The distribution pattern of melanocyte stem cells is different depending on the density of pigmented terminal hair and that of vellus hair. As compared with hair follicle stem cells, melanocyte stem cells are sparsely distributed. Volar melanocyte stem cells reside in eccrine sweat gland and require a long travel to distribute melanocytes in the epidermis. Volar melanocytes is sparse, as compared with melanocytes in hairy skin.
LETTER TO THE EDITOR
Extracorporeal photophoresis in treatment of corticosteroid refractory colitis induced by combined immunotherapy for metastatic melanoma
- Version of Record online: 11 September 2024
Assessing outcomes of cutaneous squamous cell carcinoma with large-calibre nerve invasion as solitary high-risk factor: A single-institution cohort study
- Version of Record online: 10 September 2024
SYSTEMATIC REVIEW
Predictors and mechanisms of self-stigma in five chronic skin diseases: A systematic review
- Version of Record online: 09 September 2024
Along with experiencing stigmatization in social contexts, individuals with visible chronic skin disease often deal with self-stigma. The graphical abstract depicts an adapted model from Germain and colleagues (2021) and highlights correlates, predictors and outcomes associated with self-stigma for people with atopic dermatitis, psoriasis, vitiligo, alopecia areata or hidradenitis suppurativa according to the present systematic literature review of 27 included studies. Study quality ratings were good although majority of the reviewed studies were cross-sectional and causal inferences could not be made. Psychosocial correlates to self-stigmatization with supporting evidence in both Germain and colleagues' (2021) model and the current review were noted with an asterisk (*), whereas additional correlates found in our review were emphasized in red text. Several psychosocial correlates were considered modifiable, such as social stigma, coping strategies and social support, and therefore potential targets for psychosocial interventions (highlighted in green and pathways depicted with solid green lines), while others were not (depicted with dashed grey lines). The figure also identifies measurable outcomes (highlighted in blue) for future interventions.
ORIGINAL ARTICLE
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study
- Version of Record online: 09 September 2024
Alopecia areata (AA) is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop-out were registered. In conclusion, data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.
REVIEW ARTICLE
Considerations for defining and diagnosing generalized pustular psoriasis
- Version of Record online: 06 September 2024
Generalized pustular psoriasis (GPP) is a rare chronic skin disease with inconsistent definitions and diagnostic criteria. It is characterized by widespread pustules and erythema, which are often accompanied by other signs and symptoms. Cases of suspected GPP may benefit from laboratory testing to assess organ function as well as genetic and histopathological testing to support a diagnosis. Increased awareness and education of this rare and highly variable disease will improve diagnosis and timely treatment.
SYSTEMATIC REVIEW
Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis
- Version of Record online: 06 September 2024
Isotretinoin, a vitamin A derivative primarily known for treating acne vulgaris, has been investigated for rosacea despite its off-label use. This systematic review and meta-analysis of 16 studies involving 1445 patients examined low-dose isotretinoin (defined as ≤0.5 mg/kg/day) for the four main types of rosacea. This study found significant reduction in lesion count (p = 0.03) and erythema (p = 0.01), with low-dose isotretinoin outperforming topical retinoids and antimicrobials in reducing lesion count (p = 0.03). Its effect on erythema in rosacea however, did not meet statistical significant (p = 0.18). Improvements persisted 16 weeks post-treatment, with a relapse rate of 35% at 5.5 months. Study design heterogeneity limited comprehensive comparisons. Overall, low-dose isotretinoin appears to be an effective, well-tolerated, and safe treatment for rosacea.
REVIEW ARTICLE
SYSTEMATIC REVIEW
The risk of ultraviolet exposure for melanoma in Fitzpatrick skin types I–IV: A 20-year systematic review with meta-analysis for sunburns
- Version of Record online: 04 September 2024
Risk of ultraviolet exposure and melanoma in Fitzpatrick skin types I–IV. A systematic review of 19,852 studies from January 2002 to December 2021 was performed analysing UV exposure and melanoma risk in Fitzpatrick type I–IV individuals. Twenty studies (77%, 20/26) identified a significant association between UV exposure and melanoma incidence. There is a significant ongoing association between UV exposure, specifically sunburns (unadjusted odds ratio:1.66; pooled adjusted odds ratio: 1.23) and melanoma incidence in Fitzpatrick skin types I–IV. Other forms of UV exposure were more heterogeneously captured and had mixed results. UV exposure should continue to be considered a modifiable risk factor for melanoma in individuals of Fitzpatrick skin types I–IV. Counselling on photoprotection remains valuable for mitigating the risk of melanoma in this population. Thank you to Rebecca S. Xu, MD, for creating the images for use in this graphical abstract.
ORIGINAL ARTICLE
BAUSSS biomarker improves melanoma survival risk assessment
- Version of Record online: 31 August 2024
The range of mortality risk within individual AJCC staging brackets is very wide. Administering adjuvant drug therapy based solely on AJCC T3b, T4a and T4b staging will result in many high-risk patients over 60 years of age being denied such drugs while other patients under young patients will be offered drug therapy despite having a relatively low risk primary tumour.
LETTER TO THE EDITOR
Familial Mediterranean fever and MEFV gene variants in hidradenitis suppurativa: A systematic review
- Version of Record online: 27 August 2024
Melanosis and isolated follicular vitiligo during checkpoint inhibitors for metastatic melanoma
- Version of Record online: 22 August 2024
Erectile dysfunction in patients with seborrhoeic dermatitis
- Version of Record online: 22 August 2024
Excellent response to cemiplimab and radiotherapy in advanced metastatic porocarcinoma
- Version of Record online: 22 August 2024
Recalcitrant erosive palms and soles eccrine syringofibroadenoma successfully treated with radiotherapy
- Version of Record online: 21 August 2024
A randomized single-blinded prospective study comparing simulated daylight photodynamic therapy with natural daylight photodynamic therapy for multiple actinic keratoses
- Version of Record online: 21 August 2024
Prolonged complete remission of a lymphoepithelioma-like carcinoma of the skin with bone metastases induced by pembrolizumab
- Version of Record online: 21 August 2024
ORIGINAL ARTICLE
Epidermal proteomics demonstrates Elafin as a psoriasis-specific biomarker and highlights increased anti-inflammatory activity around psoriatic plaques
- Version of Record online: 19 August 2024
Epidermal sampling of lesional, perilesional and non-lesional skin from psoriasis and eczema patients as well as healthy skin was used to perform an in depth proteomic analysis. IL-36γ known to be expressed in lesional psoriasis skin was outperformed by the protease inhibitor Elafin as a disease-specific epidermal biomarker. Elafin is a robust marker presents across psoriasis subtypes and under systemic therapy as long as active lesions are present. Mass spectrometry and ELISA analysis also demonstrated the upregulation of the anti-inflammatory molecule IL-37 in psoriatic perilesional but not lesional skin. This anti-inflammatory activity at lesion border may contribute to the sharp demarcation seen in psoriatic plaques.
REVIEW ARTICLE
Langerhans cells: Central players in the pathophysiology of atopic dermatitis
- Version of Record online: 19 August 2024
Langerhans cells (LCs) have unique properties to maintain cutaneous immunity. In atopic dermatitis (AD), LCs contribute to a variety of pathophysiological mechanisms underlying AD, such as immune response modulation, microbiome sensing, skin barrier integrity and neuro-immune communication. Despite numerous insights into their dual pro- and anti-inflammatory functions, much remains unknown. Understanding the central role of LCs in AD might enable innovative approaches to treat this complex disease.
SYSTEMATIC REVIEW
Efficacy of interventions for cutaneous squamous cell carcinoma in situ (Bowen's disease): A systematic review and meta-analysis of proportions
- Version of Record online: 16 August 2024
Graphical abstract of the study on cutaneous squamous cell carcinoma in situ, commonly known as Bowen's disease, with the primary objective of comparing the efficacies of different treatment interventions. The top right corner section depicts the methods used herein: the study begins with a systematic literature search to identify relevant studies. Subsequently, a quality assessment of the studies is conducted. Data extraction focuses on several key metrics: lesion clearance ates (LCR), participant clearance rates (PCR), lesion recurrence rates (LRR), participant recurrence rates (PRR) and baseline characteristics. The extracted data are then used to group the various interventions, including PDT, 5% 5-FU, cryotherapy and surgery, among others. Two meta-analyses of proportions are conducted for each outcome using a generalized linear mixed model: one focusing exclusively on high-quality studies, and another encompassing all study arms to ensure comprehensive results. At the bottom left, the meta-analysis process using forest plots is illustrated. The treatment efficacies are presented in descending order in treatment rankings, exemplified with a ranking of LCR. At the bottom right, the conclusions are stated: the efficacy comparison provides a thorough overview of the efficacy outcomes for practice-relevant interventions in treating Bowen's disease. Additionally, the study addresses the challenges in comparability, highlighting the variability in treatment rankings across LCR, PCR, LRR and PRR. It also discusses the limitations in comparability due to the different numbers of studies between treatment groups and outcome measures, as well as methodical and clinical heterogeneity.
LETTER TO THE EDITOR
Factors associated with long-term complete remission in pemphigus patients receiving rituximab therapy
- Version of Record online: 16 August 2024
Trending on TikTok: An analysis of melanotan content on social media
- Version of Record online: 16 August 2024
ORIGINAL ARTICLE
Happiness across the borders—A cross-sectional study among patients with psoriasis and atopic dermatitis in Europe
- Version of Record online: 14 August 2024
The study aimed to assess happiness among psoriasis and atopic dermatitis patients from 8 European countries. Patients ≥18 years of age were asked to complete a questionnaire on happiness and quality of life. Differences between psoriasis and atopic dermatitis patients and between the European countries were analysed. Psoriasis and atopic dermatitis patients showed similar levels of happiness, while patients with psoriasis showed higher quality of life. Both happiness and quality of life varied between European countries, with Austrian patients displaying the highest happiness levels. Equality in treatment access is imperative, alongside the development of targeted positive psychological interventions to enhance happiness.
LETTER TO THE EDITOR
Cutaneous leishmaniasis as immune reconstitution syndrome: A clinical and histopathological case series
- Version of Record online: 13 August 2024
Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumab
- Version of Record online: 13 August 2024
SYSTEMATIC REVIEW
Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review
- Version of Record online: 13 August 2024
Nakaseomyces glabratus (formerly known as Candida glabrata) is an endogenous opportunistic pathogen that causes various clinical manifestations, ranging from mucocutaneous overgrowth to bloodstream infections. This review aims to summarize the biology, epidemiology and pathology of N. glabratus, as well as the mechanisms of resistance to antifungal agents. We believe that a better understanding of this information can improve the management of these infections based on existing research.
LETTER TO THE EDITOR
Dupilumab may break the “itch-scratch cycle” in chronic prurigo and induce remission in a subset of patients
- Version of Record online: 09 August 2024
Doxycycline-induced fixed drug eruption: The new epidemic?
- Version of Record online: 09 August 2024
Clinical benefit from palbociclib, letrozole and goserelin combination therapy for sweat gland carcinoma with neuroendocrine differentiation (SCAND)
- Version of Record online: 08 August 2024
Coexistence of oligoclonal and polyclonal HTLV-1-positive T cells with presentation of acute-type adult T-cell leukaemia-lymphoma successfully treated by ultraviolet B phototherapy and etretinate
- Version of Record online: 08 August 2024
Dupilumab facial dermatitis in atopic dermatitis patients ameliorated by topical crisaborole: An open-label case series study
- Version of Record online: 06 August 2024
The potential role of derma-venereologists in prescribing and managing pre-exposure prophylaxis in Italy
- Version of Record online: 06 August 2024
Interactions between dupilumab and vitiligo: A scoping review
- Version of Record online: 06 August 2024
The efficacy of intravenous immunoglobulin for the treatment of pyoderma gangrenosum: A systematic review and meta-analysis
- Version of Record online: 05 August 2024
ORIGINAL ARTICLE
New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials
- Version of Record online: 05 August 2024
Hidradenitis suppurativa (HS) clusters in adults with moderate to severe HS in the SUNSHINE and SUNRISE phase 3 trials and responses to secukinumab treatment by cluster. Graphical abstract detailing three panels that describe (i) the population, study design and cluster analysis method used in this analysis; (ii) the baseline clustering analysis illustrating the three HS clusters and their characteristics and (iii) the HS clinical response in the secukinumab treatment groups from baseline to week 52 in Cluster 1, Cluster 2 and Cluster 3 and a conclusion of the analysis.
LETTER TO THE EDITOR
Dermatologic immune-related adverse events: It is time for a game change!
- Version of Record online: 02 August 2024
ORIGINAL ARTICLES
Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients—A retrospective register-based cohort study in Finland and Sweden
- Version of Record online: 02 August 2024
ORIGINAL ARTICLE
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
- Version of Record online: 01 August 2024
Methotrexate (MTX) is frequently used off-label for atopic dermatitis (AD), but there is a lack of clear dosing guidelines. This study aimed to establish consensus on MTX dosing through an eDelphi process, conducted from October 2021 to September 2022, involving dermatologists and dermatology residents. A total of 152 participants took part, with 104 completing all survey rounds and 43 attending the consensus meeting. The consensus encompassed recommendations on test doses, start and maximum doses, administration routes, dosing schedules, treatment durations and the supplementation of folic acid. The goal of this study is to guide prescribing decisions and promote a standardized global approach to MTX use in AD.
Navigating through the healthcare system with atopic dermatitis: Analysing patient journeys in Germany
- Version of Record online: 01 August 2024
Graphical representation of the patient journey for individuals with atopic dermatitis. The journey begins in the top left with the first symptoms (usually an itchy skin rash). The time until the first consultation with a doctor varies. The first point of contact is not always a doctor. Often, symptoms are first researched on the Internet or presented to acquaintances. Several weeks may pass between the initial symptoms and the diagnosis or the start of therapy. During therapy, patients may experience either satisfaction or dissatisfaction. Dissatisfied patients are more likely to abandon the therapy or seek alternative treatments. The image should illustrate that the patient journey does not always follow a fixed path.
LETTER TO THE EDITOR
Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
- Version of Record online: 31 July 2024